SUMM.L Share News (SUMM)

UK AGM, EGM Calendar - Week Ahead

REPEAT: Summit Corp Plans Dual NASDAQ Listing, Name Change As Loss Widens (ALLIPO)

Summit Corp Plans Dual NASDAQ Listing, Name Change As Loss Widens

Summit Reports Positive Data At World Muscle Society Congress

Summit Corp Says Studies Show Its SMT19969 Superior To Vancomycin

Summit Corp Widens Loss As It Progresses Drugs Through Trials

Summit chief buys 30,000 shares

AIM-listed drug developer Summit, which develops therapies for Duchenne Muscular Dystrophy and C. difficile infection, on Wednesday said its chief executive Glyn Edwards had acquired 30,000 shares. The 104.5p-a-share deal cost Edwards £31,350 and took his stake in the group to 233,333 shares. The

UK MORNING BRIEFING: Deutsche Bank Raises Shell View, Cuts BP

Summit Sees Positive Duchenne Muscular Dystrophy Drug Trial Results

Summit Says First Patients In Phase II Antibiotic Trial Dosed

UK MORNING BRIEFING: Tullow Oil Strikes Oil Offshore Norway

UK MORNING BRIEFING: Shares Down As Iraq Fighting Lifts Oil Prices

Summit Corp Appoints Erik Ostrowski As Chief Financial Officer

Summit Corp To Consolidate Share Capital, Hoping To Get New Investors

LONDON (Alliance News) - Summit Corporation PLC Tuesday said it will seek shareholder permission for a share consolidation that will see every 20 existing shares consolidated into one new share. In a statement, the drug discovery company said it will first consolidate every 20 shares into o

Summit Corp. reports progress with DMD trial, but next phase delayed

Shares in Summit Corporation suffered a fall despite giving a generally positive report of the first phase of its Duchenne Muscular Dystrophy (DMD) trial which has examined the safety and tolerance of SMT C1100. The decline may be linked to a delay in the next patient study, which is expected to no